| Heading: |
Tuberculosis: Drugs |
| Question ID: |
1815284 |
| UIN: |
61787 |
| House: |
Commons |
| Date tabled: |
2025-06-23 |
| Asking Member ID: |
4515 |
| Asking Member display name: |
Kate Osamor
|
| Asking Member handle: |
kateosamor
|
| Asking Member Twitter reference: |
@kateosamor
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the availability of tuberculosis medication on the provision of healthcare in London. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-01 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and are outside of Government control, including manufacturing difficulti... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |